AP Insights, News, Videos, and More

Patches, gums, and nasal sprays prescribed for smoking cessation were found to be as effective in reducing alcohol consumption as prescribed varenicline and cytisine, according to a new study published in the journal JAMA Network Open.

Rocky Mountain Symposium presenter John Sovec, MA, LMFT, discusses the challenges LGBTQ patients face in heteronormative treatment models, and shares best practices for delivering trauma-informed care.

James S. DiRedia, LICSW, PhD, who presented at the Rocky Mountain Symposium on Saturday, discusses the benefits and best practices of implementing a family systems approach to addiction recovery.

Rocky Mountain Symposium presenters David Nefussy and Lisa Blanchard, LMHC, of Spectrum Health Systems, discuss skills needed for ensuring appropriate documentation of care, clinical tools, and steps for aligning clinical practices with a...

Rocky Mountain Symposium on Addictive Disorders presenter Jack Perkins, DMin, LADC, CSAC, CCLC, discusses guidelines for integrating spirituality and psychotherapy.

Perfectionist traits are associated with severe alcohol use disorder (AUD), according to a new study published in the journal Alcoholism: Clinical & Experimental Research.

Treating psychiatric disorders in children and adolescents with psychotropic medication does not increase the risk of SUD. It appears to reduce the risk in individuals with pediatric ADHD, MDD, and psychotic disorders.

People who use high-potency cannabis are more likely to experience addiction than those who use low-potency products, according to a new study conducted at the University of Bath in the United Kingdom.

Widespread adoption of telehealth during the COVID-19 pandemic has kept more veterans with opioid addiction engaged in medication-assisted treatment, according to a new study by the University of Michigan and VA Ann Arbor Healthcare System.

Adial Pharmaceuticals announced that in its ONWARD Phase 3 clinical study, its AD04 medication achieved a statistically significant mean reduction in heavy drinking days among a prespecified group of “heavy drinkers” compared to a placebo.